ClinicalTrials.gg
CompletedNCT04518345Updated Feb 6, 2023

TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

An Early Phase 1 interventional study of Azacitidine and Dubermatinib in Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia and Therapy-Related Acute Myeloid Leukemia, sponsored by Uma Borate. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-06.

Sponsored by Uma Borate · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,772nd of 1,908
3 · median 35
Started
2020
with 91 others
Phase 1
772 of 2,138
127 open now
Registered
1,689th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,772nd largest by enrollment of the 1,908 interventional ones that give a count, is one of 92 that started in 2020, is one of 772 in phase 1, and was the 1,689th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This phase IB/II trial studies the best dose of TP-0903 and how well it works when given alone or with azacitidine in treating patients with FLT3 gene mutated acute myeloid leukemia. TP-0903 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TP-0903 alone or with azacitidine may kill more cancer cells.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine a tolerable dose of dubermatinib (TP-0903) monotherapy for relapsed/refractory patients with FLT3 acute myeloid leukemia (AML).

II. To determine the maximum tolerated dose (MTD) of TP-0903 with azacitidine in untreated unfit patients with FLT3 AML.

III. To determine the complete remission (CR) or complete remission with partial hematologic recovery (CRh) rate following induction therapy with TP-0903 in relapsed/refractory patients or TP-0903 with azacitidine therapy in untreated unfit patients with FLT3 AML.

SECONDARY OBJECTIVES:

I. To determine the toxicity profile of TP-0903 as a single agent and in combination with or azacitidine.

II. To determine disease-free survival for patients achieving CR/CRh in each cohort.

III. To determine overall survival for patients in each cohort. IV. To determine the proportion of patients who go to transplant.

EXPLORATORY OBJECTIVES:

I. To conduct pharmacokinetic studies of TP-0903 alone and in combination with azacitidine.

II. To examine changes in circulating AXL, Gas6, FLT3 ligand, and other cytokines/chemokines by TP-0903.

III. To determine the impact of TP-0903 on the inhibition of kinase signaling (AXL, FLT3, STAT5, AURKA), and metabolomics in AML cells.

IV. To determine differentially expressed genes in bone marrow stromal cells and AML cells upon TP-0903 treatment.

V. To examine sensitivity and resistance patterns associated with TP-0903 by genomic, epigenomic, and transcriptomic profiling.

OUTLINE: This is a phase Ib, dose-escalation study of dubermatinib followed by a phase II study.

(FLT3 AML WITH RELAPSED/REFRACTORY DISEASE):

INDUCTION: Patients receive dubermatinib orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients with clinical or hematologic response and not transplant eligible may continue dubermatinib until loss of response/clinical benefit. Patients with clinical or hematologic response and transplant eligible may continue dubermatinib until one week prior to admission.

After completion of study treatment, patients are followed up followed every 3 months for up to 2 years from registration and then every 6 months for up to 5 years from registration.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia
  • Therapy-Related Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with AML and the presence of FLT3-ITD mutation
  • Patients with secondary AML or therapy related disease (t-AML) are eligible
  • If the patient has co-morbid medical illness, attributed to this must be greater than 6 months
  • (ECOG) performance status =\< 2
  • Total \< 2.0mg/dL unless due to Gilbert's disease
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) \< 2.5 x institutional
  • Creatinine (Cr) clearance > 50 mL/min by calculation
  • (NYHA) Congestive Heart Failure (CHF) class II or better
  • Cardiac ≥40%
  • Female patients of must agree to use dual methods of and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or . For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose
  • Ability to understand and willingness to sign the written document
  • (HIV) infection without history of acquired immunodeficiency syndrome (AIDS) and sufficiently high CD4 cells (> 400/mm\^3) and low HIV viral loads (\< 30,000 copies/ml plasma) not requiring anti-HIV therapy are eligible

Exclusion criteria

Exclusion Criteria:

  • Patients with acute promyelocytic leukemia
  • Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Treatment with hydoxyurea is permitted during cycle 1 to maintain white blood cell (WBC) \< 40,000/uL
  • Patients receiving any other agents or patients that have received other investigational agents within 14 days of enrollment
  • Patients with active central nervous system (CNS)
  • Major surgery within 2 weeks before day 1
  • Uncontrolled active infection. Patients with infection requiring parenteral antibiotics are eligible if the infection is controlled
  • Patients with significantly diseased or obstructed gastrointestinal tract
  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure ( [NYHA] class III or IV), unstable angina pectoris, myocardial infarction within 6 months prior to enrollment, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any (ECG) abnormality at screening has to be documented by the investigator as not medically relevant
  • Patients with serious medical or psychiatric illness likely to interfere with participation in this clinical study
  • Pregnant women or women who are breastfeeding are excluded from this study. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for or surgically sterilized women
  • Patients with advanced malignant solid tumors
  • Patients who are not able to swallow capsules or tablets
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Treatment (dubermatinib)

    FLT3 AML WITH RELAPSED/REFRACTORY DISEASE: INDUCTION: Patients receive dubermatinib PO QD on days 1-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients with clinical or hematologic response and not transplant eligible may continue dubermatinib until loss of response/clinical benefit. Patients with clinical or hematologic response and transplant eligible may continue dubermatinib until one week prior to admission.

    Drug: Azacitidine · Drug: Dubermatinib

Interventions

  • Given IV

    Also known as: 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza

  • Given PO

    Also known as: TP 0903, TP-0903, TP0903

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose of dubermatinib (TP-0903)

    Determine a tolerable dose of TP-0903 monotherapy for relapsed/refractory patients with FLT3 AML.

    Time frame: Up to 28 days

  2. Composite complete response (CR) rate

    Will calculate the composite CR rate (complete remission \[CR\]/complete remission with incomplete count recovery \[CRh) defined according to the 2017 European LeukemiaNet Acute Myeloid Leukemia recommendation.

    Time frame: Up to 5 years post registration

  3. Composite CR rate with partial hematologic recovery (CRh) rate

    Will calculate the composite CR rate (CR/CRh), defined according to the International Working Group criteria and assessed at the end of induction.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Disease-free survival

    Will be summarized by the Kaplan-Meier method to determine disease-free survival for patients achieving complete response CR/CRh in each cohort of the study.

    Time frame: From the date of first CR/CRh until the first date of relapse/progression or death from any cause, assessed up to 5 years post registration

  2. The Number of patients who proceed to transplant

    The number of patients who got to transplant

    Time frame: Up to 5 years post registration

  3. Overall survival

    Will be summarized by the Kaplan-Meier method.

    Time frame: From the treatment start date until the date of death from any cause or date last known alive, assessed up to 5 years post registration

  4. Maximum grade of each type of adverse event

    Will be recorded for each patient and summarized.

    Time frame: Up to 5 years post registration

  5. Incidence of treatment-related adverse events

    Treatment-related adverse events, defined as possibly, probably or definitely related to study treatment per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 will be summarized separately.

    Time frame: Up to 5 years post registration

  6. Tolerability of TP-0903

    Reasons for treatment discontinuation and number of TP-0903 cycles received will be summarized and used to assess tolerability.

    Time frame: Up to 5 years post registration

Other outcomes

  1. Peak Plasma Concentration (Cmax) pharmacokinetics (PK)

    Initial analysis of plasma PK data will include standard compartmental and noncompartmental methods. Descriptive statistics including means, standard deviations, and frequencies will be computed for all variables. Relationships between continuous variables will be performed using standard linear correlation and linear regression. Relationships between PK parameters such as maximum concentration with response will be performed using standard t-tests or Wilcoxon rank sum tests and illustrated using boxplots or other graphical displays.

    Time frame: Up to 5 years post registration

  2. Area under the plasma concentration (AUC) pharmacokinetics (PK)

    Initial analysis of plasma PK data will include standard compartmental and noncompartmental methods. Descriptive statistics including means, standard deviations, and frequencies will be computed for all variables. Relationships between continuous variables will be performed using standard linear correlation and linear regression. Relationships between PK parameters such as area under curve with response will be performed using standard t-tests or Wilcoxon rank sum tests and illustrated using boxplots or other graphical displays.

    Time frame: Up to 5 years post registration

  3. Changes in cytokines/chemokines

    Differences in cytokines/chemokines will be evaluated using paired t-tests or Wilcoxon signed rank tests. Values will be log transformed as appropriate to reflect biologic plausibility. Cytokines/chemokines to be measured include: AXL, GAS6, FLT3 ligand, GM-CSF, IL-6, IL-8, RANTES, MIP-1α, MCP-1, sCD40L, EGF, VEGF

    Time frame: Up to 5 years post registration

  4. Effect of TP-0903 on inhibition of phospho-protein expression Effect of TP-0903 on inhibition of phospho-protein expression Effect of TP-0903 on inhibition of phospho-protein expression Impact of TP-0903 on kinase signaling

    Percent inhibition of phospho-protein expression in AML cells. Phospho-proteins to be measured include: phospho-FLT3, phospho-STAT5, phospho-AURKA/B, phosho-AXL

    Time frame: Up to 5 years post registration

  5. Patterns of sensitivity and resistance

    Mutational status in AML cells will be determined in samples at baseline and during treatment. Mutations in genes with single nucleotide changes and indels at variant allele frequency (VAF) \>0.1 will be reported. Mutations with decreasing VAF represent sensitivity, and increasing VAF represent resistance.

    Time frame: Up to 5 years post registration

07

Study locations

1 site
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
08

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Oct 2021, 11 months.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's 11 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2020
First posted
Aug 19, 2020
StartActual
Nov 5, 2020
Primary completionActual
Oct 13, 2021
CompletionActual
Dec 22, 2021
Last update
Feb 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04518345
Lead sponsor
Uma Borate
Responsible party
Uma Borate (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
Aug 19, 2020
Start date
Nov 5, 2020
Primary completion
Oct 13, 2021
Completion
Dec 22, 2021
Last update
Feb 6, 2023

Study contacts

Uma Borate, MD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dubermatinib

Start the discussion